ZIOPHARM ONCOLOGY 8-K 2012
Washington, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d) OF
Date of report (Date of earliest event reported): February 29, 2012
ZIOPHARM Oncology, Inc.
(Exact Name of Registrant as Specified in Charter)
(Registrant’s telephone number, including area code)
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
On February 29, 2012, ZIOPHARM Oncology, Inc. issued a press release announcing its financial condition and results of operations for the fourth quarter and year ended December 31, 2011. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
INDEX OF EXHIBITS